

**A. V. Ermolenko, Ya. A. Sotskaya**  
**INDICATORS OF CELLULAR IMMUNITY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WITH CHRONIC OBSTRUCTIVE LUNG DISEASE IN PERIOD MEDICAL REHABILITATION IN THE APPLICATION IMMUNOPLYUS AND BRONCHIPRET**

**Keywords:** gastroesophageal reflux disease, chronic obstructive lung disease, immunoplus, bronchipret, cellular immunity.

The influence of natural origin of modern immunomodulator immunoplus phytopreparation bronchipret at cellular immunity at the patients with gastroesophageal reflux disease (GERD) on background of chronic obstructive lung disease (COLD) was studied. It was set that immunoplus and bronchipret in pathogenic plan was provided to normalization of cellular immunity and in clinical plan - developing convalescence of the patients with GERD, on background COLD.

: 616.21 - 022.6 - 053.2

Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis Bordetella parapertussis [4].

[1, 3].

[1, 3, 5, 6].

[1, 3].

[2, 6].

[1].

5-15 %

[6, 7].

[7].

13.01.2005

[7].

30  
3-4-

45

75

4 15

0 3

( ),

« -500».

3-5-

. 32

: ^ 180

^ ^^

TM

(1976).

( , ± )

	(n = 40)				
	1-	3-	5-	7-	10-
	1,71 ± 0,18	1,27 ± 0,09*	0	0	0
	2,54 ± 0,14	1,90 ± 0,08*	1,30 ± 0,07**	0,60 ± 0,03***	0,07 ± 0,03
	2,34 ± 0,17	2,01 ± 0,07*	1,20 ± 0,06	0,40 ± 0,03***	0,07 ± 0,02
	1,20 ± 0,05	0,50 ± 0,02	0	0***	0
	2,51 ± 0,11	2,06 ± 0,09*	1,20 ± 0,06**	0,12 ± 0,01***	0
	(n = 30)				
	1,87 ± 0,14	1,33 ± 0,05*	0	0	0
	2,48 ± 0,13	1,78 ± 0,05*	1,50 ± 0,07**	0,90 ± 0,03***	0,06 ± 0,02
	2,42 ± 0,12	2,36 ± 0,08	1,70 ± 0,04**	0,70 ± 0,04***	0,07 ± 0,02
	1,16 ± 0,14	0,46 ± 0,04*	0	0***	0
	2,40 ± 0,12	2,12 ± 0,06*	1,10 ± 0,06**	0,44 ± 0,04***	0

\* < 0,05 -  
 \*\* < 0,05 -  
 \*\*\* < 0,05 -

1- 3-  
 3- 5-  
 5- 7-

10-12- 3 (7,5 %) 3 (8,3 %),  
 11-12  
 Mirosoft Excel 7,0 (Windows-2007). 10 92,5 %  
 91,7 %  
 3-5-  
 10 1-  
 8 1- 5  
 2-  
 3- 5  
 8  
 5-  
 3-4-  
 3-4- 10  
 3-4- 2.  
 7-10 2,

(%)

	$\pm m$	$\pm m$	( . . . , 2007)
16.0 ( )	$48,5 \pm 2,0^*$	$45,0 \pm 2,0$	$41,5 \pm 1,9$
18.0 ( )	$18,4 \pm 1,2^*$	$16,5 \pm 1,0$	$10,7 \pm 1,3$
18.1 ( )	$21,0 \pm 0,5^*$	$31,0 \pm 1,0$	$41,9 \pm 1,5$
18.2 ( )	$3,9 \pm 0,8$	$4,1 \pm 0,4$	$4,4 \pm 0,8$
18.3 ( )			
20.4 ( )	$8,2 \pm 2,0^*$	$4,3 \pm 0,5$	$1,5 \pm 0,3$
£ ( )	$66,9 \pm 1,5^*$	$61,5 \pm 1,6$	$52,2 \pm 1,5$
£ ( )	$33,1 \pm 1,5^*$	$39,4 \pm 1,6$	$47,8 \pm 1,5$
£	$12,1 \pm 1,6^*$	$8,4 \pm 0,8$	$5,9 \pm 1,4$

\* < 0,05

1. . . . . 5. . . . . 2  
 / . . . . . 5  
 // . . . . . — 1998. 18 « . . . . . »  
 — 6. — .22-25. . . . . « . . . . . »  
 2. . . . . 13.01.2005 . — . . . . . 2005. — . 58.  
 / . . . . . //Medicus Amicus. — 2005. — 5. 6. . . . .  
 3. . . . . . . . . . // Consilium Med.  
 . . . . . ( ) / . . . . . / . . . . .  
 . . . . . // . . . . . — 2005. — 3. — —2004. 7.  
 . 68-72. . . . . / . . . . .  
 4. . . . . // . . . . . — , 2011. — . 496.  
 2009. — 2, 27-37 . . . . .

21.11.2013

: 616.21 - 022.6 - 053.2

